Diagnostic Imaging's Weekly Scan: June 28 — July 4

Welcome to Diagnostic Imaging’s Weekly Scan, which offers an opportunity to catch up on the most well-viewed radiology content of the past week.

In comparison to the 2009 International Federation of Gynecology and Obstetrics (FIGO) staging system for endometrial cancer, researchers found that the updated 2023 FIGO system had over a 17 percent decrease for substage agreement between pelvic MRI and pathology findings.

In recent interviews with Diagnostic Imaging, Jeremie Calais, MD, PhD, Michael Hofman, MBBS, FRACP, Heather Jacene, MD, Phillip Kuo, MD, and more shared their thoughts about the potential impact of theranostics and what excites them about the future of nuclear medicine.

While acknowledging key limitations, the authors of a new literature review noted that contrast-enhanced mammography offers a viable alternative to conventional imaging and breast MRI for preoperative tumor evaluation and may have a significant impact on surgical management.

In his latest blog for Diagnostic Imaging, Filippo Cademartiri, MD, PhD, discusses new CCTA research that demonstrates that those with total plaque volume > 750 mm3 have an 18.6 percent risk of MACE at four years in comparison to a 1.4 percent MACE risk for those with no plaque.

For patients with known or suspected neuroendocrine tumors, the radiopharmaceutical ⁶⁴Cu-SARTATE offered over 50 percent higher average detection of liver foci than ⁶⁸Ga-DOTATATE at four hours and 20 hours post-injection, according to research presented at the recent SNMMI conference.